Patents Assigned to Polytherics Limited
-
Patent number: 11865183Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.Type: GrantFiled: February 3, 2022Date of Patent: January 9, 2024Assignee: POLYTHERICS LIMITEDInventors: Antony Godwin, Andrew Kyle, Nicholas Evans
-
Publication number: 20220193249Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.Type: ApplicationFiled: February 3, 2022Publication date: June 23, 2022Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Andrew Kyle, Nicholas Evans
-
Patent number: 11273224Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.Type: GrantFiled: April 13, 2017Date of Patent: March 15, 2022Assignee: POLYTHERICS LIMITEDInventors: Antony Godwin, Andrew Kyle, Nicholas Evans
-
Patent number: 11059903Abstract: An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: CDR1: EYTIH (SEQ ID NO: 33) CDR2: NINPNX1GGTTYNQKFED (SEQ ID NO: 34) CDR3: X2-5DY (SEQ ID NO: 35) wherein X1 is N or Q, and X2-5 is YWLF (SEQ ID NO: 39), GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), and wherein if X2-5 is GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if X2-5 is YWLF (SEQ ID NO: 39), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of disease, in particular cancers, particularly prostate cancer.Type: GrantFiled: August 18, 2017Date of Patent: July 13, 2021Assignee: POLYTHERICS LIMITEDInventors: Robert George Edward Holgate, Arron Robert Hearn
-
Patent number: 11027022Abstract: A conjugate of a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, in which the linker includes a protein or peptide bonding portion having the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which the linker also includes a cyclodextrin. The invention also provides reagents for making such conjugates.Type: GrantFiled: May 19, 2017Date of Patent: June 8, 2021Assignee: POLYTHERICS LIMITEDInventor: Antony Godwin
-
Patent number: 10835616Abstract: The invention relates to novel conjugating reagents capable of reaction with at least one nucleophile present in a peptide or protein, which contain at least one leaving group which is lost on reaction with said nucleophile, in which the leaving group includes a portion —(CH2CH2O)n—, in which n is a number of six or more; and novel processes for the preparation of conjugates containing peptides or proteins made using such reagents.Type: GrantFiled: October 8, 2015Date of Patent: November 17, 2020Assignee: POLYTHERICS LIMITEDInventors: Antony Godwin, George Badescu, Matthew Bird, Penny Bryant, David Morris, Mark Frigerio
-
Publication number: 20200268885Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.Type: ApplicationFiled: March 3, 2020Publication date: August 27, 2020Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Mark Frigerio
-
Patent number: 10654873Abstract: Provided herein are novel maytansinoid compounds of general formula I. Also provided herein are conjugates comprising the compounds linked to a binding protein via a linker, and conjugating reagents comprising the compounds attached via a linker to at least one functional group capable of reacting with a binding protein. Also provided herein are pharmaceutical compositions comprising the compounds and conjugates, therapeutic methods and uses involving the compounds and conjugates, for example in cancer therapy, and novel synthetic processes.Type: GrantFiled: September 15, 2017Date of Patent: May 19, 2020Assignee: POLYTHERICS LIMITEDInventors: Nareshkumar Jain, Sanjeevani Ghone, Sean Smith, Ian Glassford, Sylvia J. Degrado, Fu-an Kang, Senzhi Zhao
-
Publication number: 20190328893Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.Type: ApplicationFiled: April 13, 2017Publication date: October 31, 2019Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Andrew Kyle, Nicholas Evans
-
Publication number: 20190134220Abstract: A conjugate of a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, in which the linker includes a protein or peptide bonding portion having the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which the linker also includes a cyclodextrin. The invention also provides reagents for making such conjugates.Type: ApplicationFiled: May 19, 2017Publication date: May 9, 2019Applicant: POLYTHERICS LIMITEDInventor: Antony Godwin
-
Patent number: 10174125Abstract: The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(?CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.Type: GrantFiled: April 7, 2017Date of Patent: January 8, 2019Assignee: POLYTHERICS LIMITEDInventors: Antony Robert Godwin, Stephen James Brocchini
-
Patent number: 9896412Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.Type: GrantFiled: November 21, 2013Date of Patent: February 20, 2018Assignee: POLYTHERICS LIMITEDInventor: Antony Godwin
-
Publication number: 20170304461Abstract: The invention relates to novel conjugating reagents capable of reaction with at least one nucleophile present in a peptide or protein, which contain at least one leaving group which is lost on reaction with said nucleophile, in which the leaving group includes a portion —(CH2CH2O)n—, in which n is a number of six or more; and novel processes for the preparation of conjugates containing peptides or proteins made using such reagents.Type: ApplicationFiled: October 8, 2015Publication date: October 26, 2017Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, George Badescu, Matthew Bird, Penny Bryant, David Morris, Mark Frigerio
-
Publication number: 20170290925Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.Type: ApplicationFiled: October 8, 2015Publication date: October 12, 2017Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Mark Frigerio
-
Patent number: 9650331Abstract: The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(?CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.Type: GrantFiled: June 17, 2013Date of Patent: May 16, 2017Assignee: POLYTHERICS LIMITEDInventors: Antony Godwin, Stephen Brocchini
-
Patent number: 9439974Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via an amine group; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two amine groups; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via amine groups in saiType: GrantFiled: July 28, 2014Date of Patent: September 13, 2016Assignee: POLYTHERICS LIMITEDInventors: Stephen James Brocchini, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
-
Patent number: 9415115Abstract: Novel compounds of the general formula: in which X represents a polymer, Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR2 via two nucleophilic moieties.Type: GrantFiled: March 16, 2015Date of Patent: August 16, 2016Assignee: POLYTHERICS LIMITEDInventors: Antony Robert Godwin, Stephen James Brocchini
-
Patent number: 9309507Abstract: The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa.Type: GrantFiled: April 28, 2011Date of Patent: April 12, 2016Assignee: Polytherics LimitedInventor: William Henry
-
Publication number: 20150283259Abstract: Specific conjugates containing maytansines and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates.Type: ApplicationFiled: October 11, 2013Publication date: October 8, 2015Applicant: POLYTHERICS LIMITEDInventors: John Burt, Antony Godwin, Mark Frigerio, George Badescu
-
Patent number: 9005598Abstract: Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR via two nucleophilic moieties.Type: GrantFiled: March 4, 2010Date of Patent: April 14, 2015Assignee: Polytherics LimitedInventors: Antony Robert Godwin, Stephen James Brocchini